Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Cisplatin.
Aclarubicin
Cisplatin may increase the nephrotoxic activities of Aclarubicin.
Amikacin
Cisplatin may increase the nephrotoxic activities of Amikacin.
Advertisement
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Cisplatin.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Cisplatin.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Cisplatin is combined with Anthrax immune globulin human.
Advertisement
Apalutamide
The serum concentration of Cisplatin can be decreased when it is combined with Apalutamide.
Arbekacin
Cisplatin may increase the nephrotoxic activities of Arbekacin.
Azosemide
The risk or severity of ototoxicity and nephrotoxicity can be increased when Azosemide is combined with Cisplatin.
Advertisement
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cisplatin.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Cisplatin is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Cisplatin is combined with Bacillus calmette-guerin substrain tice live antigen.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Cisplatin.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Cisplatin.
Bumetanide
The risk or severity of ototoxicity and nephrotoxicity can be increased when Bumetanide is combined with Cisplatin.
Bupropion
The serum concentration of Cisplatin can be increased when it is combined with Bupropion.
Cabazitaxel
Cisplatin may increase the myelosuppressive activities of Cabazitaxel.
Clozapine
The risk or severity of adverse effects can be increased when Cisplatin is combined with Clozapine.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Cisplatin.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Cisplatin.
Daunorubicin
Cisplatin may increase the nephrotoxic activities of Daunorubicin.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Cisplatin.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Cisplatin.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Cisplatin.
Digoxin
Digoxin may decrease the cardiotoxic activities of Cisplatin.
Dihydrostreptomycin
Cisplatin may increase the nephrotoxic activities of Dihydrostreptomycin.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Cisplatin.
Docetaxel
Cisplatin may increase the myelosuppressive activities of Docetaxel.
DOCETAXEL ANHYDROUS
Cisplatin may increase the myelosuppressive activities of Docetaxel.
Doxorubicin
Cisplatin may increase the nephrotoxic activities of Doxorubicin.
Doxorubicin Hydrochloride
Cisplatin may increase the nephrotoxic activities of Doxorubicin.
Eltrombopag
The serum concentration of Cisplatin can be increased when it is combined with Eltrombopag.
Epirubicin
Cisplatin may increase the nephrotoxic activities of Epirubicin.
Ethacrynate
The risk or severity of ototoxicity and nephrotoxicity can be increased when Etacrynic acid is combined with Cisplatin.
Ethacrynic Acid
The risk or severity of ototoxicity and nephrotoxicity can be increased when Etacrynic acid is combined with Cisplatin.
Fingolimod
Cisplatin may increase the immunosuppressive activities of Fingolimod.
Fosphenytoin
The serum concentration of Fosphenytoin can be decreased when it is combined with Cisplatin.
Framycetin
Cisplatin may increase the nephrotoxic activities of Framycetin.
Furosemide
The risk or severity of ototoxicity and nephrotoxicity can be increased when Furosemide is combined with Cisplatin.
Gentamicin
Cisplatin may increase the nephrotoxic activities of Gentamicin.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Cisplatin is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Cisplatin is combined with Hepatitis B Vaccine (Recombinant).
Idarubicin
Cisplatin may increase the nephrotoxic activities of Idarubicin.
Isavuconazole
The serum concentration of Cisplatin can be increased when it is combined with Isavuconazole.
Kanamycin
Cisplatin may increase the nephrotoxic activities of Kanamycin.
kanamycin A
Cisplatin may increase the nephrotoxic activities of Kanamycin.
Leflunomide
The risk or severity of adverse effects can be increased when Cisplatin is combined with Leflunomide.
Lumacaftor
The serum concentration of Cisplatin can be decreased when it is combined with Lumacaftor.
Metrizamide
Cisplatin may increase the nephrotoxic activities of Metrizamide.
Natalizumab
The risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab.
Neomycin
Cisplatin may increase the nephrotoxic activities of Neomycin.
Netilmicin
Cisplatin may increase the nephrotoxic activities of Netilmicin.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Cisplatin.
Ouabain
Ouabain may decrease the cardiotoxic activities of Cisplatin.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cisplatin.
Paclitaxel
Cisplatin may increase the myelosuppressive activities of Paclitaxel.
Paromomycin
Cisplatin may increase the nephrotoxic activities of Paromomycin.
Phenytoin
The serum concentration of Phenytoin can be decreased when it is combined with Cisplatin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cisplatin.
Pirarubicin
Cisplatin may increase the nephrotoxic activities of Pirarubicin.
Piretanide
The risk or severity of ototoxicity and nephrotoxicity can be increased when Piretanide is combined with Cisplatin.
Plicamycin
Cisplatin may increase the nephrotoxic activities of Plicamycin.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Cisplatin.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Cisplatin is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cisplatin.
Ranolazine
The serum concentration of Cisplatin can be increased when it is combined with Ranolazine.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Cisplatin.
Rolapitant
The serum concentration of Cisplatin can be increased when it is combined with Rolapitant.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Cisplatin is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Cisplatin is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Cisplatin is combined with Salmonella typhi ty21a live antigen.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cisplatin.
Sisomicin
Cisplatin may increase the nephrotoxic activities of Sisomicin.
Spectinomycin
Cisplatin may increase the nephrotoxic activities of Spectinomycin.
Streptomycin
Cisplatin may increase the nephrotoxic activities of Streptomycin.
Streptozocin
Cisplatin may increase the nephrotoxic activities of Streptozocin.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Cisplatin.
Teriflunomide
The serum concentration of Cisplatin can be increased when it is combined with Teriflunomide.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Cisplatin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Thioctic Acid
The therapeutic efficacy of Cisplatin can be decreased when used in combination with Lipoic Acid.
Tipiracil
The serum concentration of Tipiracil can be increased when it is combined with Cisplatin.
Tobramycin
Cisplatin may increase the nephrotoxic activities of Tobramycin.
Tofacitinib
Cisplatin may increase the immunosuppressive activities of Tofacitinib.
Topotecan
The risk or severity of adverse effects can be increased when Cisplatin is combined with Topotecan.
Torsemide
The risk or severity of ototoxicity and nephrotoxicity can be increased when Torasemide is combined with Cisplatin.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Cisplatin.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Cisplatin is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Cisplatin is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Valrubicin
Cisplatin may increase the nephrotoxic activities of Valrubicin.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Cisplatin is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vemurafenib
The serum concentration of Cisplatin can be increased when it is combined with Vemurafenib.
Vinorelbine
The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinorelbine.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Cisplatin is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Cisplatin is combined with Yellow Fever Vaccine.
